US FDA approves higher dose of Biogen's genetic disorder drug

March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, the company said on Monday, offering patients a potentially more effective option. The regulator had declined to approve the company's application last year, seeking updated technical information. The therapy, Spinraza